Nine Masts Capital’s Evolent Health EVH Stock Holding History

Nine Masts Capital’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,281	Closed	-$37.1K	–	215
2026 Q1	$37.1K	Buy	+16,281	New	+$51.6K	0.01%	193

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Nine Masts Capital's EVH Position: Q2 2026 in Review

Nine Masts Capital sold out of Evolent Health (EVH) in Q2 2026, closing a stake of 16,281 shares — an estimated $37.1K sold.

Nine Masts Capital first reported a position in EVH in Q1 2026 and held it in 1 quarter. The position peaked at $37.1K in Q1 2026. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

Nine Masts Capital reported no remaining Evolent Health position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 16,281 Evolent Health shares in Q2 2026, an estimated $37.1K.
Nine Masts Capital first reported a position in Evolent Health in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Evolent Health position peaked at $37.1K in Q1 2026.
199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.